Objective responses in patients with malignant melanoma or renal cell cancer in early clinical studies do not predict regulatory approval.
about
Targeted therapy for advanced renal cell carcinomaTargeted therapy for advanced renal cell carcinomaImaging radiation response in tumor and normal tissue.Validation of novel imaging methodologies for use as cancer clinical trial end-pointsMonitoring Apoptosis of Breast Cancer Xenograft After Paclitaxel Treatment With 99mTc-Labeled Duramycin SPECT/CT.Combined assessment of metabolic and volumetric changes for assessment of tumor response in patients with soft-tissue sarcomas.Stopping rules employing response rates, time to progression, and early progressive disease for phase II oncology trials.Molecular imaging in cancer treatment.Therapeutic cancer vaccines: are we there yet?PET imaging of apoptosis in tumor-bearing mice and rabbits after paclitaxel treatment with (18)F(-)Labeled recombinant human His10-annexin V.Exposure-response relationship of AMG 386 in combination with weekly paclitaxel in recurrent ovarian cancer and its implication for dose selection.Randomized phase II designs.Immunotherapy for renal cell cancer in the era of targeted therapy.Sunitinib for advanced renal cell cancer.Anti-melanoma activity of Forsythiae Fructus aqueous extract in mice involves regulation of glycerophospholipid metabolisms by UPLC/Q-TOF MS-based metabolomics study.Phase II clinical trials in oncology: are we hitting the target?Assessing oncologic benefit in clinical trials of immunotherapy agents.Moving beyond response criteria: new measures of success in the treatment of sarcomas.Issues surrounding clinical trial endpoints in solid malignancies with a focus on metastatic non-small cell lung cancer.Statistical designs for early phases of cancer clinical trials.A pilot study for the early assessment of the effects of BMS-754807 plus gefitinib in an H292 tumor model by [(18)F]fluorothymidine-positron emission tomography.Forsythiae Fructus Inhibits B16 Melanoma Growth Involving MAPKs/Nrf2/HO-1 Mediated Anti-Oxidation and Anti-Inflammation.Beyond Correlations, Sensitivities, and Specificities: A Roadmap for Demonstrating Utility of Advanced Imaging in Oncology Treatment and Clinical Trial Design.Recommended changes to oncology clinical trial design: revolution or evolution?Outcomes of patients with metastatic melanoma treated with molecularly targeted agents in phase I clinical trials.Pre-treatment tumour perfusion parameters and initial RECIST response do not predict long-term survival outcomes for patients with head and neck squamous cell carcinoma treated with induction chemotherapy.Volumetric evaluation of hepatic tumors: multi-vendor, multi-reader liver phantom study.
P2860
Q24242946-F5D3D189-1FE0-444D-B1A4-3687942C8241Q24244090-486F470C-FBCD-417B-8FB3-3FB96EF203F0Q26798266-C7461CB5-2782-46D6-96BB-66B6602B22F6Q33394106-69ED6795-AE6E-425C-83ED-260D74BD204AQ33793574-801AB4BA-59BA-44CA-95AB-FF621C7E22F0Q33797380-90D459BE-1367-41CC-BFA6-21A7B901B275Q34094103-7F013697-663C-4D66-B0EA-AC035C42AD0FQ34496670-80E339D6-FCB1-4E97-976A-FF47BE3F5D2FQ34786691-CEEB161C-E4BC-4FF2-A7A1-3EF6CB4E9206Q34987711-18F4630B-E0FB-45F1-A1DB-0A457EFB7275Q35914787-6BBAA16C-D009-4C43-BC53-040D8C3116FCQ37173942-6B47EB04-F986-4D95-AEA8-9EC0FA4BAAB8Q37183451-7A358885-021A-4B49-917D-9E5572D220A5Q37307562-F37B0EA6-2C3B-4B23-A3DC-CE926B706C1EQ37519196-8E7601F5-6F37-490C-8454-DBD7255C305BQ37705422-46BD27FD-FD42-472E-87D3-3A53E1A2AA55Q37710860-3FF9702D-C9E8-42BC-8A51-D1F70EAFB39BQ38014354-528208D3-76A8-4AB5-94A6-102EFE9C7C41Q38026294-1DE4B053-3803-4D8A-94B9-E54E8CC82BFCQ38052915-B7BA0170-522B-497E-B361-3F5E754DB0A2Q38458343-DACFCDAD-12D5-4217-AC49-26B0CBC56276Q38757324-B1123E50-FFAC-4BA4-8B3D-88FD1961BC91Q39272347-0C20A722-6321-4B42-BDA4-048DB069923CQ43140987-D0719B3A-6819-454F-9C33-1B3A27307BE4Q44932310-B292312A-917B-42A3-BF51-1DE2669D9CEAQ52723563-466C6C8E-7F82-4663-B4E3-AC82E004DD8AQ53080830-747B9EE7-2203-49E6-8A0A-0C826369F7F0
P2860
Objective responses in patients with malignant melanoma or renal cell cancer in early clinical studies do not predict regulatory approval.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Objective responses in patient ...... t predict regulatory approval.
@ast
Objective responses in patient ...... t predict regulatory approval.
@en
type
label
Objective responses in patient ...... t predict regulatory approval.
@ast
Objective responses in patient ...... t predict regulatory approval.
@en
prefLabel
Objective responses in patient ...... t predict regulatory approval.
@ast
Objective responses in patient ...... t predict regulatory approval.
@en
P2093
P1476
Objective responses in patient ...... t predict regulatory approval.
@en
P2093
Dongsheng Tu
Dora Nomikos
John Goffin
Lesley Seymour
Stefan Baral
P304
P356
10.1158/1078-0432.CCR-05-0130
P407
P50
P577
2005-08-01T00:00:00Z